Log in

NASDAQ:EXASEXACT Sciences Stock Price, Forecast & News

$85.88
+1.99 (+2.37 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$82.06
Now: $85.88
$86.00
50-Day Range
$65.07
MA: $77.95
$86.29
52-Week Range
$35.25
Now: $85.88
$123.99
Volume1.29 million shs
Average Volume1.39 million shs
Market Capitalization$12.86 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.88
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
Read More
EXACT Sciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.65 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:EXAS
CUSIP30063P10
Phone608-284-5700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$876.29 million
Book Value$16.95 per share

Profitability

Net Income$-83,990,000.00

Miscellaneous

Employees4,110
Market Cap$12.86 billion
Next Earnings Date8/3/2020 (Estimated)
OptionableOptionable

Receive EXAS News and Ratings via Email

Sign-up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter.

EXACT Sciences (NASDAQ:EXAS) Frequently Asked Questions

How has EXACT Sciences' stock been impacted by COVID-19 (Coronavirus)?

EXACT Sciences' stock was trading at $57.82 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EXAS shares have increased by 48.5% and is now trading at $85.88. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of EXACT Sciences?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EXACT Sciences in the last year. There are currently 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for EXACT Sciences.

When is EXACT Sciences' next earnings date?

EXACT Sciences is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for EXACT Sciences.

How were EXACT Sciences' earnings last quarter?

EXACT Sciences Co. (NASDAQ:EXAS) announced its quarterly earnings results on Wednesday, May, 6th. The medical research company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.59) by $0.12. The medical research company had revenue of $347.80 million for the quarter, compared to the consensus estimate of $347.47 million. EXACT Sciences had a negative net margin of 10.04% and a negative return on equity of 13.98%. The firm's quarterly revenue was up 114.7% on a year-over-year basis. During the same period last year, the firm posted ($0.66) EPS. View EXACT Sciences' earnings history.

What guidance has EXACT Sciences issued on next quarter's earnings?

EXACT Sciences issued an update on its first quarter 2020 After-Hours earnings guidance on Tuesday, April, 21st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $348-348 million, compared to the consensus revenue estimate of $240.68 million.

What price target have analysts set for EXAS?

16 brokers have issued 1 year price targets for EXACT Sciences' shares. Their forecasts range from $70.00 to $135.00. On average, they expect EXACT Sciences' stock price to reach $106.67 in the next twelve months. This suggests a possible upside of 24.2% from the stock's current price. View analysts' price targets for EXACT Sciences.

What are Wall Street analysts saying about EXACT Sciences stock?

Here are some recent quotes from research analysts about EXACT Sciences stock:
  • 1. According to Zacks Investment Research, "Exact Sciences exited the first quarter of 2020 with better-than-expected revenues, thanks to the Genomic Health acquisition. Higher Cologuard volumes boosted its legacy Screening business. Gross margin expansion and an overall strong solvency are encouraging as well. Continued strong demand for tests needed for cancer treatment mitigated the overall revenue impact. Delivery of critical care and accelerated launch of its telehealth site to lessen direct interactions with health care providers during the pandemic are noteworthy. However, fewer patient visits and surgery deferrals due to COVID-19 are concerning. Sole reliance on Cologuard and competitive headwinds are other major downsides. Rising expenses and operating loss also do not bode well. Overall, Exact Sciences has underperformed its industry over the past six months." (5/28/2020)
  • 2. Canaccord Genuity analysts commented, "We are buyers of EXAS following the unusual 10% weakness in shares today, which we believe were part of the overall selloff today in diagnostics (and software stocks), where much of the alpha in the overall stock market has come from; and what we believe is likely certain funds pressuring EXAS following a cost effectiveness study published last week, but got a lot more attention today on the Street. We believe this is a buy-on- weakness opportunity on shares of EXAS given a handful of deep flaws used in the study." (9/10/2019)

Has EXACT Sciences been receiving favorable news coverage?

Media headlines about EXAS stock have been trending very negative on Sunday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. EXACT Sciences earned a daily sentiment score of -3.4 on InfoTrie's scale. They also gave news coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutEXACT Sciences.

Who are some of EXACT Sciences' key competitors?

What other stocks do shareholders of EXACT Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other EXACT Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), salesforce.com (CRM), Paypal (PYPL), Square (SQ), Advanced Micro Devices (AMD), Aduro BioTech (ADRO) and Netflix (NFLX).

Who are EXACT Sciences' key executives?

EXACT Sciences' management team includes the following people:
  • Mr. Kevin T. Conroy, Chairman, Pres & CEO (Age 53)
  • Mr. Jeffrey T. Elliott CFA, Chief Financial Officer (Age 41)
  • Mr. Graham P. Lidgard, Chief Science Officer (Age 70)
  • Mr. D. Scott Coward, Chief Admin. Officer, Sr. VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Mark Stenhouse, Pres of Cologuard (Age 52)

What is EXACT Sciences' stock symbol?

EXACT Sciences trades on the NASDAQ under the ticker symbol "EXAS."

Who are EXACT Sciences' major shareholders?

EXACT Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Ensign Peak Advisors Inc (2.04%), Viking Global Investors LP (1.62%), Zevenbergen Capital Investments LLC (1.20%), Geode Capital Management LLC (1.07%), Jennison Associates LLC (0.96%) and Primecap Management Co. CA (0.93%). Company insiders that own EXACT Sciences stock include D Scott Coward, G Bradley Cole, Graham Peter Lidgard, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse, Michael S Wyzga, Scott C Johnson and Thomas D Carey. View institutional ownership trends for EXACT Sciences.

Which institutional investors are selling EXACT Sciences stock?

EXAS stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Victory Capital Management Inc., Victory Capital Management Inc., Wasatch Advisors Inc., KBC Group NV, Nuveen Asset Management LLC, Kornitzer Capital Management Inc. KS, and Blair William & Co. IL. Company insiders that have sold EXACT Sciences company stock in the last year include G Bradley Cole, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse, and Scott C Johnson. View insider buying and selling activity for EXACT Sciences.

Which institutional investors are buying EXACT Sciences stock?

EXAS stock was bought by a variety of institutional investors in the last quarter, including Ensign Peak Advisors Inc, ArrowMark Colorado Holdings LLC, Sachem Head Capital Management LP, Factory Mutual Insurance Co., Viking Global Investors LP, Eminence Capital LP, Spyglass Capital Management LLC, and Rothschild & Co. Asset Management US Inc.. View insider buying and selling activity for EXACT Sciences.

How do I buy shares of EXACT Sciences?

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is EXACT Sciences' stock price today?

One share of EXAS stock can currently be purchased for approximately $85.88.

How big of a company is EXACT Sciences?

EXACT Sciences has a market capitalization of $12.86 billion and generates $876.29 million in revenue each year. The medical research company earns $-83,990,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. EXACT Sciences employs 4,110 workers across the globe.

What is EXACT Sciences' official website?

The official website for EXACT Sciences is www.exactsciences.com.

How can I contact EXACT Sciences?

EXACT Sciences' mailing address is 441 CHARMANY DRIVE, MADISON WI, 53719. The medical research company can be reached via phone at 608-284-5700.

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.